Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Head-to-head comparison of Adipotide and Survodutide — mechanism, dosing, side effects, legal status, and pricing.
Adipotide (FTPP) is a chimeric peptidomimetic developed in the Arap/Pasqualini lab (originally at MD Anderson) that couples a 9-residue homing motif (CKGGRAKDC) — isolated by in vivo phage display as a ligand for prohibitin on white-adipose-tissue vasculature — to the D-amino-acid pro-apoptotic domain D(KLAKLAK)2. It is an experimental research compound, NOT FDA-approved for any indication. A clinical-development program in prostate-cancer-associated obesity reached early-phase testing and was ultimately discontinued.
Survodutide is a dual GLP-1 / glucagon receptor agonist co-developed by Boehringer Ingelheim and Zealand Pharma. NOT FDA-approved; received FDA Breakthrough Therapy Designation in 2024 for non-cirrhotic MASH with moderate/advanced fibrosis. Phase 3 ongoing (SYNCHRONIZE in obesity/T2DM; LIVERAGE and LIVERAGE-Cirrhosis in MASH).
Adipotide
Survodutide
Category
Legal Status
Mechanism
Dose Range
Route
Frequency
COA-verified vendors · trust score ≥70 required · single-vial price — bulk/bundle deals may be lower
Adipotide
Survodutide
COA corpus from Disclosed Labs — independently tested batches only.
Adipotide
2
COAs
98.8%
Avg purity
2
Labs
Survodutide
10
COAs
99.7%
Avg purity
4
Labs
Foundational proof-of-concept in obese mice (Kolonin et al., Nat Med 2004, PMID 15133506). A 4-week dosing study in spontaneously obese rhesus macaques showed substantial body-weight and fat-mass loss and improved insulin sensitivity but produced dose-dependent renal proximal-tubule toxicity (Barnhart et al., Sci Transl Med 2011, PMID 22072637). A small Phase 1 trial in obese prostate-cancer patients was initiated and later terminated; the program was permanently discontinued. No published human efficacy data. Grey-market human use is unstudied and carries documented nephrotoxicity risk.
Phase 2 MASH trial (Sanyal et al., NEJM 2024; 48 weeks, F1–F3 fibrosis): MASH resolution without worsening of fibrosis in 47% (2.4 mg), 62% (4.8 mg), and 43% (6.0 mg) vs 14% placebo. Phase 2 obesity trial reported ~19% weight loss at 46 weeks at the highest dose. Dose-dependent heart-rate elevation has been observed.
Adipotide and Survodutide are both in the Metabolic category and may have overlapping mechanisms. Researchers should review both profiles carefully, understand the mechanisms of action, and monitor the relevant biomarkers when combining compounds in the same class. As always, consult a licensed healthcare provider before making any decisions about combining research compounds.
This platform provides informational tools only, not medical advice. This comparison is for educational purposes only. Consult a licensed provider.
Dosing Notes
Side Effects
Contraindications
Lab Testing
Disclosed Labs